Integrated Report

Overview

The report presents FY2023 net sales of ¥54,638 million and a recovery driven by allergen and skin-disease products. It sets out Torii Pharmaceutical's Purpose, Basic Policy on Sustainability, and 11 material issues. Governance disclosures show a five-member Board with three Independent Outside Directors and 20% female Directors, while environmental disclosures report FY2023 head-office and sales-vehicle CO2 emissions and a 98.6% head-office waste recycling rate.

Document

Report type: Integrated Report
Class: Embedded
Scope: Full report
Fiscal year: 2023
Period: 1 January 2023 – 31 December 2023
Language: English
Pages
File size

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services